Clinical efficacy of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) and patients' perception of improvement in alopecia areata: Results from the ALLEGRO Phase 2b/3 trial

E. Guttman-Yassky,T. Ito,A. Jabbari,J. Mackay-Wiggan,A. Lejeune,R. Wolk, D. Wajsbrot, S. H. Zwillich

EXPERIMENTAL DERMATOLOGY（2021）

Cited 0|Views2

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined